Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
OncoMed Pharmaceuticals Inc (OMED)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/23/2019 |
GN
| Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Completion of the Merger with OncoMed Pharmaceuticals, Inc. |
| 04/19/2019 |
GN
| Report: Exploring Fundamental Drivers Behind Murphy Oil, Clean Harbors, OncoMed Pharmaceuticals, RiceBran Technologies, Zedge, and Aptose Biosciences — New Horizons, Emerging Trends, and Upcoming Developments |
| 04/18/2019 |
GN
| Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") Merger Update: Acquisition of OncoMed Pharmaceuticals, Inc. ("OncoMed") – Result of OncoMed Stockholder Meeting |
| 03/15/2019 |
GN
| OncoMed Pharmaceuticals Declares Special Dividend of Contingent Value Rights |
| 12/05/2018 |
GN
| Proposed Combination of Mereo BioPharma and OncoMed Pharmaceuticals |
| 11/15/2018 |
GN
| Recent Analysis Shows Construction Partners, OptimizeRx, OncoMed Pharmaceuticals, Issuer Direct, Red Violet, and Golden Minerals Market Influences — Renewed Outlook, Key Drivers of Growth |
| 11/09/2018 |
GN
| OncoMed Announces Early Clinical Data for anti-TIGIT Antibody |
| 10/20/2018 |
GN
| OncoMed Announces Interim Phase 1b Results for Navicixizumab and Paclitaxel Combination Therapy in Platinum-resistant Ovarian Cancer |
| 10/09/2018 |
GN
| OncoMed Announces Upcoming Presentation of Navicixizumab Interim Phase 1b Data at the European Society of Clinical Oncology Meeting |
| 09/24/2018 |
GN
| OncoMed to Present at the Cantor Global Healthcare Conference |
| 08/02/2018 |
GN
| OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights |
| 04/18/2018 |
GN
| OncoMed Presents Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting |
| 03/19/2018 |
GN
| OncoMed Announces Appointment of John Lewicki, PhD, as President, Chief Executive Officer and a member of the Board of Directors |
| 03/08/2018 |
GN
| OncoMed Announces Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights |
| 01/04/2018 |
GN
| OncoMed Provides 2018 Outlook and 2017 Year-End Cash Balance and Announces an Update on the Rosmantuzumab Program |
| 01/04/2018 |
GN
| OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings has Resigned |
| 11/27/2017 |
GN
| OncoMed Announces Chairman, President and Chief Executive Officer Paul J. Hastings to Resume Chairman Responsibilities |
| 11/02/2017 |
GN
| OncoMed Announces Third Quarter 2017 Financial Results and Operational Highlights |
| 10/24/2017 |
GN
| OncoMed Pharmaceuticals to Report Third Quarter Financial Results and Operational Highlights on November 2nd, 2017 |
| 09/19/2017 |
GN
| OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence |
| 09/13/2017 |
GN
| OncoMed Doses First Patient with GITRL-Fc in Phase 1a Clinical Trial |
| 07/26/2017 |
GN
| OncoMed Pharmaceuticals to Report Second Quarter Financial Results on August 2nd, 2017 |
| 05/08/2017 |
GN
| OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results |
| 05/03/2017 |
GN
| OncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017 |
| 04/24/2017 |
GN
| OncoMed Announces Workforce Reduction |
| 04/17/2017 |
GN
| OncoMed's Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints |
| 04/10/2017 |
GN
| OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept |
| 04/10/2017 |
GN
| OncoMed's Phase 2 Demcizumab Pancreatic Cancer Trial Misses Primary Endpoint |
| 04/03/2017 |
GN
| OncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017 |
| 03/08/2017 |
GN
| OncoMed Pharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results |
| 03/02/2017 |
GN
| OncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017 |
| 03/01/2017 |
GN
| OncoMed Pharmaceuticals to Report Fourth Quarter and Year End Financial Results on March 8, 2017 |
| 02/13/2017 |
GN
| OncoMed Enrolls First Patient in Phase 1b Clinical Trial of its Anti-DLL4/VEGF Bispecific Antibody in Patients with Platinum-Resistant Ovarian Cancer |
| 02/08/2017 |
GN
| OncoMed Pharmaceuticals to Present at the BIO CEO and Investor and Leerink Global Healthcare Conferences |
|
|